Datadog Inc vs ImmunityBio Inc. Common Stock — how do they compare? Datadog Inc trades at $293 (market cap $98.31B), while ImmunityBio Inc. Common Stock trades at $10.51 (market cap $10.51B). The key difference: Datadog Inc is far larger — about 9.4× ImmunityBio Inc. Common Stock's market cap, and Datadog Inc is trading nearer its 52-week high, ImmunityBio Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Datadog Inc for 76 Days and ImmunityBio Inc. Common Stock for 1 Days on average.
| DDOG | IBRX | |
|---|---|---|
Market Cap | $98.31B | $10.51B |
Volume | 2,936,660 | 10,445,785 |
Sector | Technology | Health |
52-Week High | $288.15 | $11.55 |
52-Week Low | $102.62 | $1.98 |
Typical Hold Time | 76 Days | 1 Days |
Enterprise Value | $94.61B | $10.97B |
Signals from Pluang's Aura AI — not financial advice
Datadog (DDOG) trades at $293.26, up 8.08% in the last session, showing strong momentum with consistent earnings beats in recent quarters. The stock exhibits bullish technical signals with moving averages supporting upward trends, while fundamentals reveal robust revenue growth from $2.7B in 2024 to $3.4B in 2025. Recent news highlights accelerating AI and enterprise customer expansion, with FBN Securities initiating coverage with an Outperform rating.
Investment outlook remains positive given strong analyst consensus (83% buy ratings) and accelerating AI-driven growth, though elevated valuation ratios (P/E 547.6, P/S 25.33) pose risks if growth moderates. Key risks include competitive pressure in cloud monitoring and dependence on enterprise spending cycles. The stock trades above the $276.10 consensus target, suggesting near-term upside may be limited despite bullish sentiment.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →